Literature DB >> 9853690

A review of developmental aspects of cytochrome P450.

J R Oesterheld1.   

Abstract

This article surveys the development of human hepatic P450 cytochromes (CYPs) involved in xenobiotic metabolism from the fetus through the life span and explores possible clinical consequences of developmental issues. These hepatic P450 CYPs come "on line" at different times during fetal and infant development, and each one is discussed in that temporal sequence. CYP3A7. the major fetal hepatic cytochrome, is present during organogenesis, and it is involved in steroid metabolism. Variably expressed in some fetuses, CYP3A5 is also present at significant levels in about half of all children. In adults, CYP3A4 is the major functional member of the CYP3A subfamily. CYP1A1 is also present during organogenesis, and it metabolizes exogenous toxins, some of which are procarcinogens. CYP2E1 may be present in some second-trimester fetuses, and it may be involved in prenatal alcohol metabolism. After birth, hepatic CYP2D6 and CYP2C8/9 and CYP2C18/19 become active. Both CYP2D6 and CYP2C19 have genetic polymorphisms that can bring about differing capacities to metabolize exogenous drugs, including psychotropic drugs. CYP1A2 becomes active in the fourth to fifth postfetal months. It provides the best current examples of the importance of developmental changes in xenobiotic-metabolizing P450 CYPs through its metabolism of caffeine and theophylline in premature infants, neonates, and adolescents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853690     DOI: 10.1089/cap.1998.8.161

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  17 in total

1.  Caffeine, selected metabolic gene variants, and risk for neural tube defects.

Authors:  Rebecca J Schmidt; Paul A Romitti; Trudy L Burns; Jeffrey C Murray; Marilyn L Browne; Charlotte M Druschel; Richard S Olney
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-07

Review 2.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Comparative docking studies of CYP1b1 and its PCG-associated mutant forms.

Authors:  Malkaram Sridhar Achary; Hampapathalu Adimurthy Nagarajam
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

Review 4.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

5.  Developmental toxicity of dextromethorphan in zebrafish embryos/larvae.

Authors:  Zheng Xu; Frederick E Williams; Ming-Cheh Liu
Journal:  J Appl Toxicol       Date:  2010-08-24       Impact factor: 3.446

6.  Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide.

Authors:  Elke De Wachter; Jesse Vanbesien; Iris De Schutter; Anne Malfroot; Jean De Schepper
Journal:  Eur J Pediatr       Date:  2003-04-26       Impact factor: 3.183

7.  MATERNAL GRAVES DISEASE AND ABNORMAL CYP2D6 GENOTYPE WITH FETAL HYPERTHYROIDISM.

Authors:  Christopher Spoke; Christopher Martin
Journal:  AACE Clin Case Rep       Date:  2020-04-03

8.  Caffeine in apnoeic Asian neonates: a sparse data analysis.

Authors:  How Sung Lee; Yok Moi Khoo; Yazmin Chirino-Barcelo; Kim Leong Tan; Dorothy Ong
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

9.  Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.

Authors:  S L Kacinko; H E Jones; R E Johnson; R E Choo; M A Huestis
Journal:  Clin Pharmacol Ther       Date:  2008-08-13       Impact factor: 6.875

10.  Maternal caffeine intake during pregnancy is associated with birth weight but not with gestational length: results from a large prospective observational cohort study.

Authors:  Verena Sengpiel; Elisabeth Elind; Jonas Bacelis; Staffan Nilsson; Jakob Grove; Ronny Myhre; Margaretha Haugen; Helle Margrete Meltzer; Jan Alexander; Bo Jacobsson; Anne-Lise Brantsaeter
Journal:  BMC Med       Date:  2013-02-19       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.